Visa (V) Tops Q4 EPS by 5c

October 24, 2016 4:06 PM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Visa (NYSE: V) reported Q4 EPS of $0.78, $0.05 better than the analyst estimate of $0.73. Revenue for the quarter came in at $4.26 billion versus the consensus estimate of $4.23 billion.

We continue to deliver healthy earnings growth in the face of continued, but abating headwinds. We have begun to see the benefits from our acquisition of Visa Europe and strong cost discipline helped our results. At the same time, we are unwavering in our commitment to invest in client partnership opportunities and the further build out of our digital payments capabilities,” said Charlie Scharf, Chief Executive Officer of Visa Inc.

“As we enter fiscal 2017, we are positioned well as revenue headwinds will continue to ease, we will continue to see the benefits from Visa Europe in our results, and our strong client franchise continues to grow,” added Scharf.

Financial Outlook for Fiscal Full-Year 2017:

Visa Inc. provides its financial outlook for the following GAAP metrics for fiscal full-year 2017:

  • Annual net revenue growth: 16% to 18% range on a nominal dollar basis, including 1.0 to 1.5 ppts of negative foreign currency impact;
  • Client incentives as a percent of gross revenues: 20.5% to 21.5% range;
  • Annual operating margin: Mid 60s;
  • Effective tax rate: Low 30s; and
  • Annual diluted class A common stock earnings per share growth: Low 30s on a GAAP nominal dollar basis and mid-teens on an adjusted, non-GAAP nominal dollar basis (see note below), both including 1.5 to 2.0 ppts of negative foreign currency impact.

For earnings history and earnings-related data on Visa (V) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings, Hot Earnings

Related Entities

Earnings, Definitive Agreement

Add Your Comment